Trial Profile
A phase I trial of EC0652 for the non-invasive diagnosis of tumors expressing prostate-specific membrane antigen (PSMA) receptors in patients with advanced prostate cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Apr 2016
Price :
$35
*
At a glance
- Drugs EC 0652 (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
- 07 Apr 2016 New trial record